Navigation Links
Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Date:9/25/2011

Stockholm, Sweden: Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

Professor Richard Gelber told delegates at the 2011 European Multidisciplinary Cancer Congress [1], in Stockholm today (Monday 26 September) that a 12-year update of results from the Breast International Group (BIG) 1-98 [2] trial showed that if women with early breast cancer (cancer that has not spread from the breast) were given letrozole after surgery for at least five years, they continued to do better and have fewer recurrences of the disease than those who were given tamoxifen.

"Over a median of eight years of follow-up, women who were assigned to receive five years of letrozole after surgery had an 18% reduced risk of relapse and a 21% reduced risk of death compared with those assigned to receive tamoxifen," said Prof Gelber, Director of the International Breast Cancer Study Group (IBCSG) Statistical and Data Management Center at the Dana-Farber Cancer Institute, Boston, MA, USA.

"The current 12-year update is the longest follow-up to date and includes much more information than we had after ten years. For instance, there have been 32% more relapses and 39% more deaths since the ten-year update, which increases substantially the reliability of the results and provides reassurance regarding the long-term value of letrozole. This additional follow-up and accumulation of information on relapses and deaths show that the overall survival advantage for adjuvant letrozole compared to tamoxifen continues to be statistically significant."

Adjuvant therapy (treatment that is given after surgery), using drugs that target hormones such as oestrogen, is given to patients with early breast cancer who
'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Study sheds light on aromatase inhibitor joint pain syndrome
2. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
3. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
4. BRAF inhibitor shows promising preclinical activity against melanoma
5. JAK inhibitor provides rapid, durable relief for myelofibrosis patients
6. Novel biomarker may predict response to new VEGF receptor inhibitor
7. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
8. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
9. JAK inhibitors producing significant response in myelofibrosis patients
10. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
11. Combining 2 peptide inhibitors might block tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country ... patients becomes a serious challenge. Because of growing competition, it is more important ... local community. , The team at Wound Care Advantage has found ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program entitled " Lovetraction Lines ." It's for women interested in improving their ... they desire. The course, which officially launched to the public early this morning, ...
(Date:7/30/2015)... ... 30, 2015 , ... The American Telemedicine Association (ATA) is ... focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract over ... place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the ...
(Date:7/30/2015)... ... ... 24/7 Care At Home, a high-quality provider of comprehensive home health care ... for Medicare and Medicaid (CMS) have awarded its agency the highest star rating available ... agency is one of three top Orange County agencies to earn the 5-Star distinction. ...
(Date:7/30/2015)... ... 30, 2015 , ... Ross A. Clevens, MD, FACS has been ... of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious school. ... developing a strong presence and a valuable mentoring program for medical students. ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... , , , Springfield ... Call on Senator, Congressmen to Tackle Issue , , ... may be taking a break from Washington, AARP is making sure ... broken health care system. With a giant inflatable Rx bottle ...
... , , , ... Resources (Spectrum) recently passed The Joint Commission,s intra-cycle certification, ... a staffing firm,s ability to provide competent staffing services. ... Approval, which the organization received in 2008. , ...
... , WASHINGTON and BOSTON, Sept. 1 ... LLC today announced a strategic partnership to deliver comprehensive ... IT, and M. Beacon Enterprises, business process and organizational ... meet the urgent needs of businesses preparing for the ...
... , , , , ... NTRI ), a leading provider of weight management programs ... to offer consumers striving for a late-summer shape up, some easy, top-of-mind ... long. , , According to Sansone, ...
... , Medicaid Savings Could Surpass $59 ... 1 Expanding health centers to reach an additional 20 ... health care savings of $212 billion over the ten-year period 2010 to ... these expected savings far exceeds the cost of the health center investment ...
... WASHINGTON, Sept. 1 , , WHAT: Chronic viral hepatitis is ... that costs the nation,s health system hundreds of, ... attention. As many as 2 million people in the United States are, ... chronically infected with hepatitis C. However, most do not ...
Cached Medicine News:Health News:Sen. Durbin, Congressmen Get Health Care Reform 'Message in a Bottle' from AARP 2Health News:Joint Commission Recognizes Spectrum Healthcare Resources 2Health News:Approach Group, Inc. and M. Beacon Enterprises, LLC Announce Strategic Partnership to Provide End-to-End Business Continuity Planning 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 4Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 5Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 6Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 2Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 3Health News:National Summit on Viral Hepatitis to be Held September 10-11 in Washington, D.C. 2Health News:National Summit on Viral Hepatitis to be Held September 10-11 in Washington, D.C. 3
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
(Date:7/30/2015)... , July 30, 2015  Growth of the ... as they bring former prescription users to the OTC ... Kline forecasts robust Rx-to-OTC switch activity over the ... emerging along with many new brands entering the market ... over the next five years (even those with low ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... GUANGZHOU, China, Oct. 30 /PRNewswire-Asia/ -- ... Medicine" or "the Company"), a developer,and leading ... medicines ("TCM"), nutritional and dietary supplements,and medical ... through its,wholly-owned subsidiary in China, Konzern Pharmaceuticals, ...
... , TAIPEI, Taiwan, Oct. ... WHC,2009 in Beijing: from bench to bedside and ... management. This solution entails a series of,innovative ... screening, diagnosis, and treatment follow-up. Microlife successfully,developed ...
Cached Medicine Technology:China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 4Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 2Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 3
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: